Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AstraZeneca’s Epanova: Third In Omega-3 Market, Potentially First With Larger Population Claim

This article was originally published in The Pink Sheet Daily

Executive Summary

Fish oil treatment is the first to offer a dosing regimen of as few as two capsules, once a day, with our without food, AstraZeneca said.

You may also be interested in...

Deals Of The Week Examines How Amarin Reeled In A Partner For Vascepa

Amarin signed Kowa Pharmaceuticals America as a commercial partner for its fish oil pill, more than doubling the number of sales reps detailing the medicine. Forma signed a second drug discovery pact with Celgene, while Baxter bolstered its hemophilia franchise by buying out partner Chatham Therapeutics.

AstraZeneca’s Soriot Outlines Epanova Approach, Reviews Tough First Year As CEO

AstraZeneca’s two-pronged approach to get its experimental fish oil-based heart drug Epanova approved by U.S. regulators is on track according to CEO Pascal Soriot. But an FDA Advisory Committee’s negative recommendation for Amarin’s similar drug, Vascepa, likely means the second step, seeking a label expansion for Epanova in a broader, less seriously ill population, will have to await full outcomes data.

Cholesterol Drug Approvals May Hinge On Outcomes Studies; FDA Rejects Diabetes-style Tiered Trials

Decreasing cardiovascular events is the only endpoint that matters for cholesterol-lowering drugs, FDA official says at Amarin’s negative Vascepa panel, leaving little room for drug’s expanded approval based on a surrogate endpoint.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts